HR Execs on the Move

Manifold Bio

www.manifold.bio

 
A next-generation protein therapeutics company pioneering an in vivo biologics design platform. By redesigning in vivo measurement to be available from day one, Manifold Bio has an advantage in solving complex biologic challenges.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Gleb Kuznetsov
Co Founder and Chief Executive Officer Profile

Similar Companies

Regenexx

The Regenexx Procedures are a family of non-surgical stem cell and blood platelet treatments for common injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient’s own stem c...

Genera Energy

Genera Energy provides a robust and integrated biomass supply solution for the advanced biofuels, biopower, and biobased products industries.

Vividion

Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company`s cutting-edge platform was spun out of the labs of Vividion`s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.

Saltwhistle Technology

Saltwhistle Technology is a Chester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tessera Therapeutics

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.